Eyconis

Eyconis uses the TransCon prodrug platform to create long‑acting, sustained‑release formulations of ophthalmic medicines, enabling controlled drug delivery inside the eye for months to years. By covalently linking active agents to a biodegradable carrier, the company aims to reduce the frequency of intravitreal injections for retinal diseases such as wet AMD, diabetic macular edema, retinal vein occlusion, and geographic atrophy, improving patient adherence and visual outcomes.

Traction 10/10

Redwood City, United States · HQ

Founded 2024451K+ followers

Biotechnology
Healthcare Technology

Updated 5 months ago

Funding

Raised to date

$25MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

Mark Bachleda

Chief Executive Officer

Product

Problem

Patients with retinal diseases such as wet age‑related macular degeneration, diabetic macular edema, retinal vein occlusion, and geographic atrophy require frequent intravitreal injections of biologics, leading to high treatment burden, adherence challenges, and suboptimal outcomes.

Solution

Eyconis leverages an exclusive worldwide license to the TransCon technology platform to create long‑acting, sustained‑release formulations of clinically validated and emerging ophthalmic medicines. By covalently linking active drug molecules to a biodegradable carrier, TransCon enables controlled release over extended periods, reducing injection frequency while maintaining therapeutic exposure. The platform is adaptable to multiple drug classes, allowing Eyconis to develop best‑in‑class therapies across the major causes of blindness. This approach aims to improve patient convenience, adherence, and visual outcomes while delivering value to healthcare systems.

Target Audience

Primary customers are pharmaceutical companies developing retinal disease therapeutics and ophthalmologists seeking longer‑acting treatment options for patients with AMD, DME, RVO, and GA.

Features

TransCon prodrug platform that provides sustained intra‑ocular release of active agents for months to years
Compatibility with a broad range of biologics and small‑molecule ophthalmic drugs
Proprietary chemistry enabling precise control of release kinetics and drug stability
Scalable manufacturing process designed for ophthalmic formulation and sterile fill‑finish
Preclinical and early clinical data supporting reduced injection frequency without loss of efficacy